Key result
Hemoadsorption ticagrelor removal cuts major perioperative bleeding ~46% in urgent CABG patients.
Why the study?
Guidelines recommend ticagrelor discontinuation for at least 72 hours prior to CABG, but intraoperative removal during surgery may reduce perioperative bleeding.
Does intraoperative ticagrelor removal using a hemoadsorption device reduce major bleeding in patients on ticagrelor undergoing isolated CABG before completing washout?
Does intraoperative ticagrelor removal using a hemoadsorption device reduce major bleeding in patients on ticagrelor undergoing isolated CABG before completing washout?
Intraoperative ticagrelor removal using a hemoadsorption device significantly reduces major perioperative bleeding in patients undergoing urgent CABG without completing the recommended washout period.
Answers are grounded in this paper and cite their sources.
May allow urgent CABG before ticagrelor washout; confirms hemoadsorption benefit in RCT.
All articles of this category (opens in new window) Background: Guidelines recommend ticagrelor discontinuation for at least 72 hours prior to CABG. A novel polymer hemoadsorption device is capable of removing ticagrelor during on-pump cardiac surgery. STAR-T was a North American randomized, double-blind, sham-controlled trial investigating intraoperative ticagrelor removal with this device to reduce perioperative bleeding in cardiac surgery. The International STAR Registry (STAR-R) collects real-world outcomes with antithrombotic drug removal by the same device. Methods: STAR-T randomized patients 1:1 to the device or sham, whereas all STAR-R patients received the device. The device was integrated into the cardiopulmonary bypass (CPB) circuit. Inclusion/exclusion criteria from STAR-T were applied to STAR-R to identify patients on ticagrelor undergoing isolated CABG before washing out. Device-treated patients were pooled and compared to STAR-T controls. Patient-level data were analyzed with a primary endpoint of major bleeding defined as the composite of Universal Definition for Perioperative Bleeding (UDPB ≥ 3) or 24-hr chest tube drainage (CTD) ≥ 1 L. Results: The pooled cohort comprised 153 device-treated patients and 60 controls, with a mean age was 64.4 ± 9.6 years and 84% males. Demographics and baseline characteristics were balanced, except for the time from last ticagrelor dose to CABG, which was significantly shorter in device-treated patients (28.8 ± 16.4 vs. 38.6 ± 14.6 hours, p < 0.001). Operation (4.3 ± 1.3 vs. 4.2 ± 1.2 hours, p = 0.710) and CPB (95.3 ± 35.9 vs. 94 ± 34.4 minutes, p = 0.801) durations were similar. Major bleeding was significantly reduced in device-treated patients compared with controls (16.3% vs. 30.0%, p = 0.02), corresponding to a number needed to treat of seven to prevent a major bleed. Multivariate logistic regression identified age and the use of the device as independent predictors of post-CABG major bleeding. Conclusion: Pooled data from a randomized trial and a real-world registry show that intraoperative ticagrelor removal with a novel device reduces major perioperative bleeding in patients undergoing CABG before completing the recommended washout. Publication History Article published online: 17 February 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
No takes yet. Share an insight, caveat, or question.
Schmoeckel et al. (2026) studied Urgent CABG in patients on ticagrelor (n=213). Intraoperative ticagrelor removal with a polymer hemoadsorption device vs. Sham or standard care was evaluated on Major bleeding (composite of Universal Definition for Perioperative Bleeding ≥ 3 or 24-hr chest tube drainage ≥ 1 L) (NNT 7, p=0.02). Intraoperative ticagrelor removal with a hemoadsorption device reduced major perioperative bleeding from 30.0% to 16.3% in patients undergoing CABG before completing washout.
Synapse has enriched 10 related papers. Consider them for comparative context: